Price Alert

Zevra Therapeutics Inc. (ZVRA)

NASDAQ: ZVRA · Real-Time Price · USD

9.64

0.13 (1.37%)

At close: Aug 22, 2025, 2:16 PM

1.37% (1D)

Bid	9.63
Market Cap	541.15M
Revenue (ttm)	62.02M
Net Income (ttm)	2.64M
EPS (ttm)	-0.25
PE Ratio (ttm)	-38.56
Forward PE	16.87
Analyst	Strong Buy

Ask	9.66
Volume	514,238
Avg. Volume (20D)	1,170,808
Open	9.56
Previous Close	9.51
Day's Range	9.27 - 9.83
52-Week Range	6.19 - 13.16
Beta	1.87

About ZVRA

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol ZVRA

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for ZVRA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Zevra Therapeutics has released their quartely earnings on Aug 12, 2025:

Revenue of $25.9M exceeds estimates by $3.35M, with 482.15% YoY growth.

EPS of 1.24 misses estimates by -0.16, with 358.33% YoY growth.

Next Earnings Release

Zevra Therapeutics Inc. is scheduled to release its earnings on Nov 11, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-19.81%

Zevra Therapeutics shares are trading lower after ... Unlock content with Pro Subscription

1 month ago

+5.14%

Zevra Therapeutics are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $26 price target.

News

1 week ago · zacks.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)

Zevra Therapeutics (ZVRA) came out with a quarterly earnings of $1.21 per share versus the Zacks Consensus Estimate of $2.19. This compares to a loss of $0.48 per share a year ago.

1 week ago · seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Off...

1 week ago · zacks.com

Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates

Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $1.43. This compares to a loss of $0.48 per share a year ago.

1 week ago · zacks.com

3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.

1 week ago · zacks.com

What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'

Zevra Therapeutics (ZVRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it t...

2 weeks ago · zacks.com

Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth

Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago · zacks.com

Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?

The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement a...

1 month ago · zacks.com

Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice

Does Zevra Therapeutics (ZVRA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · zacks.com

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

1 month ago · zacks.com

Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable,...

Load More News